Personalized Diagnosis and Treatment of Hematological Malignancies

Dear Colleagues,

Years of basic science and translational research have led to a surge in precision diagnostics and treatments in hematologic malignancies. The growing number of immunotherapies, targeted, and cellular therapies available and currently being studied in the treatment of myeloid, lymphoid, and plasma cell malignancies has created tremendous excitement for the individualization and advancement of treatment approaches in the years to come. Providers are no longer limited to highly toxic classical chemotherapy in the management of these diseases, allowing for the treatment of older and frailer patients, expanding the potential for benefit into the eighth and even ninth decades of life, adding both years to patients’ lives and life to their years. However, there remains an endless quest to improve outcomes and quality of life through further development and research in hematologic malignancies.

This Special Issue will highlight the personalized diagnosis and management of hematologic malignancies in adults, including the use of precision diagnostics, targeted therapies, immuno- and cellular therapies, and supportive care.

We cordially invite original research and review submissions focused on, but not limited to, the following topics:

• Modern approaches to the management of acute myeloid leukemia and myelodysplastic syndromes;
• New insights into the use of measurable residual disease testing and monitoring in myeloid, lymphoid, and plasma cell malignancies;
• Advances in the sequencing and use of cellular therapies including stem cell transplantation and chimeric antigen receptor T-cell (CAR-T) therapies in lymphoid malignancies;
• Personalized treatment selection/planning for patients with chronic leukemias;
• Recent advances in supportive care in adults with hematologic malignancies.

Dr. Adam S. Zayac
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.